Peptide·plain sequence-like
Glutathione
ATLPC0015432
ECG
Routes
- Length3 aa
- Monoisotopic mass
Stack
ATLPC0015432
ECG
Is the peptide identity interpretable at sequence or structure-string level?
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
Is this peptide linked to approved or named product context?
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
What safety, toxicity, or tolerability evidence is attached?
Can every measurement be reviewed in one cross-domain table?
Can the peptide identity be checked against reported names, sequence notation, and reference links?
Can this profile view be reproduced from structured records?
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Features are shown only when a reported notation or topology record supports them.
| PEPstrMOD model |
| predicted |
| 3 aa |
Grouped composition is often more interpretable than a long amino-acid list.
The same three research-facing layers are used across ADMETatlas.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1287.5 μg*h/mL | Comparable | LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood | Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling | Open |
| 2 | 645.5 μg*h/mL | Comparable | LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood | Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling | Open |
| 3 | 517.8 μg*h/mL | Comparable | LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood | Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 103.9 μg/mL | Comparable | LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood | Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling | Open |
| 2 | 45.5 μg/mL | Comparable | LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood | Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling | Open |
| 3 | 42.8 μg/mL | Comparable | LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood | Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 13.6 h 48960 seconds | Comparable | LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood | Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling | Open |
| 2 | 15.8 h 56880 seconds | Comparable | LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood | Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling | Open |
| 3 | 9.9 h 35640 seconds | Comparable | LC-HRMS targeted metabolomics; 24 h serial capillary whole-blood sampling; baseline-adjusted PK parameters; Table 3 manual extraction · human · whole blood | Route: oral · Dose/window: 0-24 h post-dose serial whole-blood sampling | Open |
cell monolayer
barrier evidence
The identity reference does not expose a sequence string.
ECG
ECG
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.